Advance notice of a request for proposals - permanent coronary drug-eluting stents
29 September 2017
What we need
PHARMAC is interested in receiving proposals for dual and/or sole supply market share of permanent coronary drug-eluting stents (DES) used in District Health Board (DHB) hospitals in New Zealand, for a three-year term.
We intend to release a request for proposals in early November, seeking proposals for the following:
Dual suppliers with 10% discretionary variance
DHBs must purchase from a choice of two suppliers selected brands of permanent coronary DES, in 90% of cases, with the discretion to purchase outside this range in 10% of cases.
Single supplier with 35% discretionary variance
DHBs must purchase from a single supplier, a selected brand of permanent coronary DES, in 65% of cases, with the discretion to purchase outside this range in 35% of cases.
What we don't want
PHARMAC would not be interested in receiving proposals that include:
- other types of coronary stents, including but not limited to: bare metal, covered, coronary graft system or bioresorbable stents; or
- non-coronary stents; or
- other medical devices.
What's important to us
- be WAND registered; CE or TGA or FDA certified;
- be fit for purpose and clinically appropriate for the majority of patients in New Zealand; and
- have clinical trial data which would support its use in the majority of patients requiring stenting.
Suppliers would need to be capable of meeting:
- New Zealand DHB supply and service requirements, including, but not limited to, holding three month’s stock in New Zealand at all times; and
- New Zealand DHB education and clinical support requirements.
Why should you bid?
If you are a supplier that holds a PHARMAC non-exclusive national agreement which includes permanent coronary DES, or are a supplier that would like to supply DHB hospitals with these devices in the near future, then this would likely be your only opportunity to secure a majority of the DHB market in the next three years.
Background - Interventional Cardiology Category
In April 2014, PHARMAC invited suppliers to submit their registrations of interest to supply products in scope of the Interventional Cardiology category. From that process, PHARMAC has negotiated non-exclusive national contracts with 13 suppliers. For more background information about the national contracting in this category, please visit our interventional cardiology webpage.
PHARMAC has been working to determine strategies going forward regarding managing future assessment, standardisation, prioritisation, and procurement of interventional cardiology devices that best meet patient care requirements. PHARMAC has sought objective clinical advice from the Interventional Cardiology Advisory Group (ICAG) and identified permanent coronary DES as a group of devices well suited for progression to market share procurement – the next stage of development on the pathway to full budget management.
A bit about us
PHARMAC is the New Zealand government agency that decides which pharmaceuticals to publicly fund in New Zealand. PHARMAC makes choices about DHBs' spending on vaccines, community and cancer medicines. PHARMAC also makes decisions about the medicines funded in DHB hospitals and is working towards budget management of hospital medicines and medical devices.
Interested? What's next?
We intend to go to market in early November 2017. The opportunity will also be advertised on the Government Electronic Tenders Service (GETS) website(external link).
PHARMAC will hold one supplier briefing meeting in Auckland in the week following the publication of the DES Market Share RFP on GETS.
Date: Wednesday, 15 November 2017
Location: Takaparawhau Board Room, BNZ Partners Business Centre, Level 8 - Deloitte Tower, 80 Queen Street, Auckland 1010
If you have any questions about this Advance Notice you can email PHARMAC at firstname.lastname@example.org or call our toll-free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.
Last updated: 19 November 2019